Table of Contents

Relevance tier by entity

Entity Tier Description
BL 2 Role of CPXM2 mutations in BL requires confirmation

Mutation incidence in large patient cohorts (GAMBL reanalysis)

BL

pathology Collection N mutated Incidence CI
BL GAMBL without Panea 309 3 0.0096 [0,0.0205]
BL GAMBL without ICGC/Zhou 320 6 0.0121 [2e-04,0.0241]
BL GAMBL with Panea 410 7 0.0119 [0.0014,0.0224]
BL BLGSP 219 2 0.0091 [0,0.0217]
BL Zhou/ICGC 90 1 0.0111 [0,0.0328]
BL Panea 101 4 0.0396 [0.0016,0.0776]

DLBCL

Failed to render page: conflicting chdir during another chdir block

FL

Failed to render page: conflicting chdir during another chdir block

Mutation pattern and selective pressure estimates

Failed to render page: conflicting chdir during another chdir block

Failed to render page: conflicting chdir during another chdir block

Expression

History

%%{init: { 'logLevel': 'debug', 'theme': 'dark' } }%% timeline title Publication timing 2022-07-06 : Burkhardt : BL

References

1.
Burkhardt B, Michgehl U, Rohde J, Erdmann T, Berning P, Reutter K, Rohde M, Borkhardt A, Burmeister T, Dave S, Tzankov A, Dugas M, Sandmann S, Fend F, Finger J, Mueller S, Gökbuget N, Haferlach T, Kern W, Hartmann W, Klapper W, Oschlies I, Richter J, Kontny U, Lutz M, Maecker-Kolhoff B, Ott G, Rosenwald A, Siebert R, von Stackelberg A, Strahm B, Woessmann W, Zimmermann M, Zapukhlyak M, Grau M, Lenz G. Clinical relevance of molecular characteristics in Burkitt lymphoma differs according to age. Nat Commun. 2022 Jul 6;13(1):3881. PMCID: PMC9259584

Citing

If you use the information or data from this site, please cite

Krysta Coyle, Kostiantyn Dreval, Daniel Hodson and Ryan D. Morin. Audit of B-cell cancer genes. Blood Adv (2025) 9 (8): 2019–2031.

Disclaimer

The content in these pages has been populated, in part, by an automated process. Although we have scrutinized every page to ensure accuracy, errors will inevitably exist. If you find an error please report it as an issue and we will address it.

License

This work is licensed under a Creative Commons Attribution 4.0 International License.

You are free to:

Share — copy and redistribute the material in any medium or format for any purpose, even commercially.

Adapt — remix, transform, and build upon the material for any purpose, even commercially. The licensor cannot revoke these freedoms as long as you follow the license terms.